Clinical Trials of Xenotransplantation: Waiver of the Right to Withdraw from a Clinical Trial Should Be Required
David Bourget (Western Ontario)
David Chalmers (ANU, NYU)
Rafael De Clercq
Ezio Di Nucci
Jonathan Jenkins Ichikawa
Jack Alan Reynolds
Learn more about PhilPapers
Journal of Law, Medicine & Ethics 35 (2):265-272 (2007)
Xenotransplantation pits clinical research ethics against public health needs because recipients must undergo long-term, perhaps life-long, surveillance for infectious diseases. This surveillance requirement is effectively an abrogation of the right to withdraw from a clinical trial. Ulysses contracts, which are advance directives for future care, may be an ethical mechanism by which to balance public health needs against limitation of individual rights
|Keywords||No keywords specified (fix it)|
|Categories||categorize this paper)|
Setup an account with your affiliations in order to access resources via your University's proxy server
Configure custom proxy (use this if your affiliation does not provide a proxy)
|Through your library|
References found in this work BETA
Ryan Spellecy (2003). Reviving Ulysses Contracts. Kennedy Institute of Ethics Journal 13 (4):373-392.
Citations of this work BETA
Maxwell J. Mehlman & Jessica W. Berg (2008). Human Subjects Protections in Biomedical Enhancement Research: Assessing Risk and Benefit and Obtaining Informed Consent. Journal of Law, Medicine & Ethics 36 (3):546-549.
Terrance McConnell (2010). The Inalienable Right to Withdraw From Research. Journal of Law, Medicine & Ethics 38 (4):840-846.
Eric Chwang (2008). Against the Inalienable Right to Withdraw From Research. Bioethics 22 (7):370-378.
Søren Holm (2011). Withdrawing From Research: A Rethink in the Context of Research Biobanks. [REVIEW] Health Care Analysis 19 (3):269-281.
Robert M. Sade (2007). Introduction: Reflections on Emerging Technologies at the Centennial of Organ Transplantation. Journal of Law, Medicine and Ethics 35 (2):235-237.
Similar books and articles
Charles Weijer, Characterizing the Population in Clinical Trials: Barriers, Comparability, and Implications for Review.
Mark Sheehan & Steve Clarke (2009). The Duty to Disclose Adverse Clinical Trial Results. American Journal of Bioethics 9 (8):24 - 32.
S. Matthew Liao, Mark Sheehan & Steve Clarke (2009). The Duty to Disclose Adverse Clinical Trial Results. American Journal of Bioethics 9 (8):24-32.
Maurie Markman (2004). The Research Misconception. International Journal of Applied Philosophy 18 (2):241-252.
Audrey R. Chapman & Courtney C. Scala (2012). Evaluating the First-in-Human Clinical Trial of a Human Embryonic Stem Cell-Based Therapy. Kennedy Institute of Ethics Journal 22 (3):243-261.
Marcin Waligora (2013). A European Consistency for Functioning of RECs? We Just Lost Our Chance. Journal of Medical Ethics 39 (6):408-409.
Danielle Laudy (2009). End of Life Pediatric Research: What About the Ethics? [REVIEW] Journal of Academic Ethics 7 (1-2):87-91.
Benjamin Djulbegovic (2007). Articulating and Responding to Uncertainties in Clinical Research. Journal of Medicine and Philosophy 32 (2):79 – 98.
Sven Ove Hansson (2006). Uncertainty and the Ethics of Clinical Trials. Theoretical Medicine and Bioethics 27 (2):149-167.
Stanley H. Shapiro, Charles Weijer & Benjamin Freedman, Reporting the Study Populations of Clinical Trials. Clear Transmission or Static on the Line?
George Howard (2010). Statistical Power, the Belmont Report, and the Ethics of Clinical Trials. Science and Engineering Ethics 16 (4):675-691.
Sara Vollmer & George Howard (2010). Statistical Power, the Belmont Report, and the Ethics of Clinical Trials. Science and Engineering Ethics 16 (4):675-691.
John Banja & Boadie Dunlop (2009). Enhancing Informed Consent in Clinical Trials and Exploring Resistances to Disclosing Adverse Clinical Trial Results. American Journal of Bioethics 9 (8):39-41.
Added to index2010-08-31
Total downloads4 ( #593,908 of 1,938,583 )
Recent downloads (6 months)1 ( #449,297 of 1,938,583 )
How can I increase my downloads?